Novo Nordisk (NVO) announced that its FLOW clinical trial found that Ozempic — the pharma giant's landmark GLP-1 weight-loss drug originally developed for diabetes treatment — can reduce the risk of kidney disease by 24%. Following these promising results, the Danish pharmaceutical company plans to apply for label expansions for Ozempic in the United States and Europe. Yahoo Finance's Seana Smith and Brad Smith breaks down the details. For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live. Editor's note: This article was written by Angel Smith
Novo Nordisk (NVO) announced that its FLOW clinical trial found that Ozempic — the pharma giant's landmark GLP-1 weight-loss drug originally developed for diabetes treatment — can reduce the risk of kidney disease by 24%. Following these promising results, the Danish pharmaceutical company plans to apply for label expansions for Ozempic in the United States and Europe.
Yahoo Finance's Seana Smith and Brad Smith breaks down the details.
For more expert insight and the latest market action, click here to watch this full episode of Yahoo Finance Live.
Editor's note: This article was written by Angel Smith
Reuters
Global shares eased below their recent highs on Tuesday, as the start of China's week-long annual session of parliament lacked any big-ticket stimulus plans, leaving investors disappointed, while bitcoin remained tantalisingly close to record peaks. Equity markets took a knock from a retreat from record highs on Wall Street on Monday, as the U.S. Federal Reserve showed no signs of being in a rush to cut interest rates. It also unveiled plans to issue 1 trillion yuan ($139 billion) in special ultra-long term treasury bonds, which are not included in the budget.
Reuters
Novo Nordisk's widely used diabetes drug Ozempic delayed progression of chronic kidney disease in diabetes patients, a large late-stage study found, cutting the risk of major cardiac events and death by 24%. The trial results are the latest indication that drugs from the GLP-1 class, which suppress appetite by mimicking gut hormones, have medical benefits for conditions beyond type 2 diabetes and weight-loss, their initial purposes. Around 40% of people with type 2 diabetes have chronic kidney disease and some 700 million patients are affected globally, according to the Danish drugmaker.
Associated Press Finance
Doctors and nurses at a premier Chicago children's hospital can again access patients' electronic medical records, more than a month after a cyberattack forced Lurie Children's Hospital to take its networks offline. The hospital provided the update Monday and said its phone system also is fully functioning. Officials had previously blamed the attack on a “known criminal threat actor” and said the hospital shut down its own systems for phone, email and medical records once the breach was discovered on Jan. 31.
Associated Press Finance
Michael Bloomberg, the former New York City mayor, gave the most to charitable causes last year, followed by Nike co-founder Phil Knight and his wife, Penny, and Michael Dell and his wife, Susan, according to the Chronicle of Philanthropy’s exclusive list of the 50 Americans who donated the largest sums to nonprofits last year. Bloomberg contributed $3 billion to support the arts, education, environment, public health, and programs aimed at improving city governments around the world, while the Knights gave $1.24 billion, including support for the University of Oregon and an ambitious poverty-fighting effort in Portland, Oregon. The Dells contributed nearly $976 million to their charitable funds, which distribute gifts to a wide array of charities.
Bloomberg
(Bloomberg) -- Gold jumped to an all-time high after speculation over a Federal Reserve pivot and geopolitical risks underpinned a rally in the precious metal.Most Read from BloombergAmerica Blew Almost $2 Trillion. Make It Stop.Apple’s iPhone Woes in China Deepen With a 24% Sales PlungeSupreme Court Rules Trump Can Appear on Presidential BallotsAMD Hits US Roadblock in Selling AI Chip Tailored for ChinaWall Street’s DEI Retreat Has Officially BegunBullion rose as much as 1.3% to $2,141.79 an ou
Read more --->